fingolimod hydrochloride has been researched along with Pulmonary Disease, Chronic Obstructive in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnawi, J; Davies, LT; Haberberger, R; Hamon, R; Hodge, G; Hodge, S; Pitson, SM; Reynolds, PN; Roscioli, E; Tran, HB; Ween, M | 1 |
1 other study(ies) available for fingolimod hydrochloride and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Cigarette smoke inhibits efferocytosis via deregulation of sphingosine kinase signaling: reversal with exogenous S1P and the S1P analogue FTY720.
Topics: Bronchi; Cells, Cultured; Epithelial Cells; Fingolimod Hydrochloride; Gene Expression Regulation, Enzymologic; Humans; Immunosuppressive Agents; Lysophospholipids; Macrophages, Alveolar; Phagocytosis; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Pulmonary Disease, Chronic Obstructive; Signal Transduction; Smoking; Sphingosine | 2016 |